Correction to: Clinical and Translational Oncology 10.1007/s12094-023-03203-8
In the sentence beginning “Therefore, tucatinib–lapatinib–capecitabine…” in this article, the text “tucatinib–lapatinib–capecitabine” should have read “tucatinib–trastuzumab–capecitabine” and the correct sentence should read as follows:
Therefore, tucatinib–trastuzumab–capecitabine may be a good option for patients treated with previous T-DM1 and/or T-Dxd [II, B].
The original article has been corrected.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Jose Angel Garcia-Saenz, Email: jgsaenz@salud.madrid.org.
Isabel Blancas, Email: isabelblancas@hotmail.com.
Isabel Echavarria, Email: iechavarriadg@gmail.com.
Carmen Hinojo, Email: Carmen.hinojo@scsalud.es.
Mireia Margeli, Email: mmargeli@iconcologia.net.
Fernando Moreno, Email: fmorenoa@salud.madrid.org.
Sonia Pernas, Email: spernas@iconcologia.net.
Teresa Ramon y Cajal, Email: tramon@santpau.cat.
Nuria Ribelles, Email: nunuria.ribelles.sspa@juntadeandalucia.es.
Meritxell Bellet, Email: mbellet@vhio.net.